Kena Betancur Corbis News Getty images
Pfizer on Monday he will lie down on the development of his experimental Pillowa slimming pill After the patient experienced hepatic injury, which was potentially caused by the drug in the examination.
The patient did not experience any symptoms related to the liver or side effects, said Pfizer spokesman in the statement. They added that the patient's liver enzymes “quickly recovered” after they stopped taking a pill, which is an oral GLP-1 drug called Danuglipron. The statement suggests that the patient's liver enzymes were increased, which is often indicates cell damage in the organ and it is problem It was related to other obesity drugs.
The spokesman said that the case took place in a trial that quickly increased the pill dose in a short time. Pfizer's decision to stop the development of the drug occurred after “review of all information, including all clinical data generated so far for Dauglipron and the recent contribution of regulatory bodies”, as released.
“Although we are disappointed to stop the development of Danuglipron, we are involved in the assessment and development of promising programs to bring patients innovative new drugs,” said Dr. Chris Boshoff, the main scientific officer of Pfizer. He added that the company is still developing other slimming drugs.
The advertisement adds a number of failures in the company's offer to win a piece of dynamically developing GLP-1S market, which imitates some intestinal hormones to weaken the appetite and regulate blood sugar levels. Pfizer is one of several drug manufacturers to bring a more convenient medicine for slimming in a space dominated by weekly injections, but it is years behind competitors, such as Eli Lilly AND Novo Nordisk.
Some analysts from Wall Street expect that the GLP-1 industry will be worth over $ 150 billion in the early 1930s. Oral GLP-1 may increase to be worth $ 50 billion in this sum, while the injections take into account the rest, according to the rest Some analysts estimates.
This is not the first Pfizer with Dauglipron, especially. Business interrupted The pill version twice a day in December 2023 after patients had problems tolerated in the medium stage.
But the pfizer seemed to be confident in the form of a dauglipron in July, when he said it would be like that Start research In the second half of the year, assessment of many pill doses.
Despite the decision to scrap the drug, Pfizer said on Monday that the research achieved key goals and confirmed a specific form and dose of the pill with the potential of providing “competitive effectiveness and tolerance” in late studies.
The company also noticed that the rate Increased liver enzymes In people who took Dauglipron, they are in line with approved GLP-1 drugs, based on the security of over 1,400 patients who took the Pfizer pill.
The Pfizer scored a different pill of obesity once a day in June 2023. After the patients who took this drug had a higher level of liver enzyme in the middle of the stage. Since then, investors are pessimistic about the company's potential in the GLP-1 space.
Still, the pfizer has Other experimental Obesity drugs in his pipeline in the early stages of development, which seem to work differently than its currently treatment. This includes an oral drug that blocks another intestinal hormone called Gipr, which last year entered the second test phase, and additional oral GLP-1 once a day in the first research.
Pfizer believes that gipr -focused drugs can be more effective and easier for patients, told investors former scientific director Mikael Dolsten, who since then left the company in October. He added that “there are so many applications for GLP-1”.
Danieglipron Pfizer promotes weight loss by aiming at GLP-1, thus slimming injection Novo Nordisk Wegova and diabetes treat Ozmpic. The slimming injection of Ela Lilly Zepbound and diabetes was shot by Mounjaro Target GLP-1, but also activates another intestinal hormone called GIP.
The only oral GLP-1 approved by Food and Drug Administration is Rybelsus Novo Nordisk, which treats type 2 diabetes and has won around $ 3.38 billion turnover in 2024
Pfizer's announcement appears on Monday when the company regains the basics and regains the price of the action After a quick decline in your company from Covid. Pfizer bet on the preparation of anti -cancer drugs to ensure long -term growth, but emphasized that obesity is a key goal.